Abstract
Purpose
Methods
Findings
Implications
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsReferences
Joint United Nations Programme on HIV/AIDS. Global Report: UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/en/resources/campaigns/globalreport2013/globalreport. Accessed April 30, 2015.
- Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2012.HIV Surveillance Supplemental Report. 2014; 19: 3
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Dept of Health and Human Services. April 8, 2015; A1-P20. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 30, 2015.
Gilead Sciences, Inc. [press release]. Gilead submits new drug application to U.S. Food and Drug Administration for tenofovir alafenamide (TAF)-based single tablet regimen for HIV. http://www.gilead.com/news/press-releases/2014/11/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-tenofovir-alafenamide-tafbased-single-tablet-regimen-for-hiv. Accessed April 30, 2015.
Tybost [package insert]. Foster City, CA: Gilead Sciences, Inc; 2014. http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/tybost/tybost_pi.pdf. Accessed April 30, 2015.
Stribild [package insert]. Foster City, CA: Gilead Sciences, Inc; 2014. http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/stribild/stribild_pi.ashx. Accessed April 30, 2015.
- Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV type 1-infected patients: week 48 results.J Infect Dis. 2013; 208: 32-39
Norvir [package insert]. North Chicago, IL: AbbVie, Inc; 2015. http://www.rxabbvie.com/pdf/norvirtab_pi.pdf. Accessed August 17, 2015
- Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer.ACS Med Chem Lett. 2010; 1: 209-213
- Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity.Clin Pharmacol Ther. 2010; 87: 322-329
- Toxicological significance of mechanism-based inactivation of cytochrome P450 enzymes by drugs.Crit Rev Toxicol. 2007; 37: 389-412
- Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions.Drug Metab Dispos. 2007; 35: 246-255
- Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.Antimicrob Agents Chemother. 2012; 56: 5409-5413
- Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.J Acquir Immune Defic Syndr. 2010; 55: 323-329
- Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study.J Clin Pharmacol. 2014; 54: 640-648
Evotaz [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015. http://packageinserts.bms.com/pi/pi_evotaz.pdf. Accessed April 30, 2015.
Prezcobix [package insert]. Titusville, NJ: Janssen Therapeutics; 2015. https://www.prezcobix.com/shared/product/prezcobix/prescribing-information.pdf. Accessed April 30, 2015.
- Metabolism and excretion in humans of the pharmacoenhancer GS-9350.Presented at: 11th International Workshop on Clinical Pharmacology of HIV Therapy. April 7-9, 2010; (Sorrento, Italy; Abstract 18)
- Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.Antimicrob Agents Chemother. 2014; 58: 2564-2569
- Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment.Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy. April 16-18, 2012; (Barcelona, Spain; Abstract P_38)
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.AIDS. 2011; 25: F7-F12
- Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection.AIDS. 2011; 25: 1881-1886
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.Lancet. 2012; 379: 2439-2448
- A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results.J Acquir Immune Defic Syndr. 2013; 63: 96-100
- A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results.J Acquir Immune Defic Syndr. 2014; 65: e118-e120
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial.Lancet. 2012; 379: 2429-2438
- A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results.J Acquir Immune Defic Syndr. 2013; 62: 483-486
- A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results.J Acquir Immune Defic Syndr. 2014; 65: e121-e124
- Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.HIV Clin Trials. 2014; 15: 269-273
- Cobicistat-boosted darunavir in HIV-1 infected adults: Week 48 results of a phase IIIb, open-label single-arm trial.AIDS Res Ther. 2014; 11: 39
- 48 week study of the first PI-based single tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) vs. cobicistat (COBI)-boosted darunavir (DRV) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve (TN) adults.Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 5-9, 2014; (Washington, D.C.; Abstract H-647c)
- Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.HIV Clin Trials. 2014; 15: 51-56
- Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.Lancet Infect Dis. 2014; 14: 581-589
- Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.Lancet Infect Dis. 2014; 14: 590-599
- Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.HIV Clin Trials. 2014; 15: 218-230
- Subgroup analyses of 144-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF).Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 5-9, 2014; (Washington, D.C.; Abstract H-642)
- Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.J Acquir Immune Defic Syndr. 2012; 61: 32-40
European Medicines Agency. Tybost 150 mg film-coated tablets. Summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002572/WC500153014.pdf. Accessed April 30, 2015.
- Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents.J Acquir Immune Defic Syndr. 2013; 64: 45-50
- Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.Clinicoecon Outcomes Res. 2013; 5: 437-445